Steve Treon is the Director of the Bing Center for Waldenstrom’s Macroglobulinemia (WM) at the Dana Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group.
His laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 using whole genome sequencing. Professor Treon’s laboratory also identified that Bruton’s tyrosine kinase (BTK) was a downstream target of mutated MYD88, and enabled a clinical trial with the BTK inhibitor ibrutinib that resulted in the first-ever approval of a drug by the U.S. FDA and the European Medicines Agency for WM. Professor Treon also made major contributions to the investigation and advancement of many novel agents used to treat WM including monoclonal antibodies, nucleoside analogues, bendamustine, proteasome inhibitors, and BTK inhibitors.
Please join the Waldenstroms's Macroglobulinemia Foundation of Canada for a free virtual education program for hematologists and medical specialists. Professor Treon will discuss the latest advances in Waldenstrom’s Macroglobulinemia from diagnosis to living with Waldenstrom's macroglobulinemia.
Participants will learn about the newest treatment options, signs and symptoms, clinical trials, and managing side effects. The impact of COVID 19 and the vaccine will be discussed. We will also review key questions to discuss with your patients, quality of life and the future of Waldenstrom’s treatment.
Black Physicians of Canada's annual virtual summit taking place on February 12th, 2022 from 1- 4:15 pm EST. This year we will be showcasing brilliant Black leadership in healthcare across Canada. Our keynote speaker is Liben Gebremikael, executive director of TAIBUFind out more »
Presentation Title: Treosulfan-Based Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS): the Princess Margaret Hospital Experience
1. To review the modern approach to the treatment of myelodysplastic syndrome (MDS), including non-transplant and transplant options.
2. To review the available information on the outcomes of allogeneic hematopoietic cell transplantation (HCT) for MDS.
3. To review the available evidence supporting the use of treosulfan-based conditioning for allogeneic HCT in MDS.
4. To present the experience with treosulfan-based conditioning for allogeneic HCT in MDS at Princess Margaret Hospital.
This content-rich meeting provides a forum for Canadian clinicians, trainees, and allied health care professionals to share the latest hematology news with an emphasis on ASH 2021. The focus of this meeting on what does this news means and where are we taking it.
We’ll discuss and address relevant issues and innovations in hematology, presented by leading Canadian experts and framed from a Canadian perspective.Find out more »
Please see flyer for full details.Find out more »
Dr. Carolyn Owen, FRCPC Associate Professor Division of Hematology & Hematological Malignancies University of Calgary Hematologist, Tom Baker Cancer Centre Calgary, AlbertaFind out more »
The educational program provides insights on managing CLL from a Canadian and International perspective. The content has been designed to improve the knowledge and skills of clinicians who manage patients with CLL . Practical treatment strategies including evidence based best practices aligned with guideline recommendations will be discussed. Presenters will engage in a clinical exchange to address key clinical questions in CLL.
Peter Hillmen, MB ChB, FRCP, FRCPath, PhD
Dr. Carolyn Owen, FRCPC
For full details see flyer: WMFC Canada Grand Rounds JCastillo 2022-05-19Find out more »
This year's conference will be hosted in hybrid format at the Volvo Congress Center in Bologna, Italy from May 25-27, 2022 with the ISLH Educational Workshop Day preceding the conference on May 24th.
• Lectures on the Latest Topics in Laboratory Hematology
• Pre-Meeting Full Day Educational Workshop (May 24, 2022)
• Special Plenary Sessions
• Corporate Luncheon Workshops
• Oral Abstract and Poster Sessions
• Commercial Exhibits
• Attend Either In-Person or Online
At the end of the session participants will be able to:
1. Discuss the indications for initiation of therapy for patients with chronic lymphocytic leukemia.
2. Describe the front-line treatment options for chronic lymphocytic leukemia using a case-based approach.
3. Apply the principles of risk-adapted treatment using case-based scenarios to illustrate the impact of patient attributes and disease specific attributes in the management of chronic lymphocytic leukemia.
4. Discuss the various available front-line treatment options within the Canadian landscape.